Multiple sclerosis: disease modifying therapy and the human leukocyte antigen
Abstract: Objective: To investigate the potential relationship between the human leukocyte antigen (HLA) type (class I and II) and the response to several disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS). Methods: We analyzed clinical data of 87 patients with MS at the beginning and end of each type of DMT including the disease duration, Expanded Disability Status Scale and Multiple Sclerosis Severity Score (MSSS). Genotyping of HLA-DRB1, HLA-DPB1, HLA-DQB1, HLA-A, HLA-B and HLA-C alleles were identified using high-resolution techniques. Statistical correlation between the HLA type and response to DMTs was done using the initial and final MSSS. Results: Statistical relationships (p < 0.05) were found for only 15 of 245 alleles tested. There was a reduction in the MSSS for patients treated with corticosteroids (DRB1*15:01, DPB1*04:01, DQB1*02:01 and DQB1*03:01), azathioprine (DRB1*03:01, DPB1*04:01, DQB1*03:02, DQB1*06:02, HLA-C*07:02), interferon -1a 22 mcg (DRB1*11:04, DQB1*03:01 and DQB1*03:02), interferon -1a 30 mcg (DPB1*02:01, HLA-C*05:01) and interferon -1b (DQB1*02:01). Conclusion: These findings suggest a few relationships between the HLA and response to DMTs in the disability for some types of HLA class I and II alleles in a specific subset of MS patients.
- Weitere Titel
-
Esclerose mltipla: teraputica modificadora da doena e antgenos leucocitrios humanos
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Multiple sclerosis: disease modifying therapy and the human leukocyte antigen ; volume:76 ; number:10 ; year:2018 ; pages:697-704
Arquivos de neuro-psiquiatria ; 76, Heft 10 (2018), 697-704
- Beteiligte Personen und Organisationen
-
Werneck, Lineu Cesar
Lorenzoni, Paulo Jos
Kay, Cludia Suemi Kamoi
Scola, Rosana Herminia
- DOI
-
10.1590/0004-282X20180103
- URN
-
urn:nbn:de:101:1-2023100512574522428786
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Werneck, Lineu Cesar
- Lorenzoni, Paulo Jos
- Kay, Cludia Suemi Kamoi
- Scola, Rosana Herminia
Ähnliche Objekte (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Modifying disease therapy in multiple sclerosis and breast cancer: case report
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Current Disease-Modifying Therapies in Multiple Sclerosis
Modifying disease therapy in multiple sclerosis and breast cancer: case report
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Current Disease-Modifying Therapies in Multiple Sclerosis
Modifying disease therapy in multiple sclerosis and breast cancer: case report
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis